Assessing the Efficacy of New Chemical Compounds in Treating Alzheimer's disease in Animal Models

Abstract

Alzheimer's disease (AD) is a severe condition that causes damage to the nervous system. The present approach of treating AD is inefficient at bringing the condition under long-term management and is also linked to a number of adverse consequences, including dyskinesia. The creation of non-dopaminergic remedies for AD aims to produce therapeutics that may alleviate motor deficiencies without running the risk of the chronic side effects connected with conventional dopaminergic drugs. One such target is the mGluR4 metabotropic glutamate receptor, which is now the focus of research. The possibility exists to propose mGluR4 activation as a new and promising therapy for Parkinson's disease. Additionally, applying a positive allosteric modulator to the orthosteric glutamate site rather than using direct acting agonists is seen to be a legitimate and effective therapy option for AD. The development of preclinical drugs has also benefited from the use of animal models. To evaluate a candidate compound's effectiveness, safety, and pharmacokinetics, animal testing can be done. Clinical trials on humans are being conducted as a result of promising results from therapeutic approaches that target A, tau, neuroinflammation, or other pathogenic characteristics. Additionally, non-pharmacological therapies that have shown cognitive advantages in AD models, including as exercise and environmental enrichment, have been examined in animal models.